Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab

Clin J Gastroenterol. 2020 Jun;13(3):316-319. doi: 10.1007/s12328-019-01060-z. Epub 2019 Nov 9.

Abstract

Advances in cancer chemotherapy have increased the opportunities of treating patients with cancer with renal dysfunction. Here we report the case of a 64-year-old woman with recurrent colorectal cancer who was treated with bevacizumab (BEV) combination chemotherapy. Although proteinuria caused by BEV developed early during the treatment and her renal function gradually deteriorated, BEV combination chemotherapy could be continued for 48 cycles over 2.5 years for controlling disease progression without other adverse events such as hypertension, decreased serum albumin level, or edema. After BEV discontinuation, proteinuria gradually improved and further renal function deterioration was not observed. Because the therapeutic options available for metastatic colorectal cancer are limited, balancing the risks and benefits of continuing chemotherapy is important in cases of adverse events.

Keywords: Bevacizumab; Colorectal neoplasms; Proteinuria; Renal insufficiency; Risk assessment.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Immunological / administration & dosage
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / administration & dosage
  • Bevacizumab / adverse effects
  • Bevacizumab / therapeutic use*
  • Capecitabine / administration & dosage
  • Capecitabine / therapeutic use
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasm Recurrence, Local / pathology
  • Oxaliplatin / administration & dosage
  • Oxaliplatin / therapeutic use
  • Proteinuria / chemically induced

Substances

  • Antineoplastic Agents, Immunological
  • Oxaliplatin
  • Bevacizumab
  • Capecitabine